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Abstract 
 
Introduction: A number of researches suggest smoking serves as a form of 
self-medication to reduce the side effects of antipsychotic medications, to 
alleviate negative symptoms, and/or to ameliorate a number of cognitive 
deficits associated with schizophrenia. Objective: The aim of this study was to 
investigate the association of cigarette smoking with verbal working memory 
and psychopathology of patients with schizophrenia. Methods: Fifty-three 
patients with schizophrenia were assessed by a single rater using the Malay 
Version of Auditory Verbal Learning Test (MVAVLT) and Positive and 
Negative Syndrome Scale (PANSS). Smokers (n=30) were compared with 
nonsmokers (n=23) on socio-demographic, clinical, psychopathology and 
verbal memory variables. Single linear and multiple regression analysis were 
performed to determine factors associated with verbal memory performance. 
Results: Verbal working memory performance is associated with lower 
number of admission to ward, lesser severity of the negative symptoms or 
general psychopathology of schizophrenia and use of atypical antipsychotics 
in all schizophrenic subjects. Smokers with schizophrenia scored higher than 
non- smoker in measures that reflect immediate memory, delayed recall and 
recognition memory. However, the association between verbal working 
memory performance and smoking status was found to be not significant. 
Conclusion: Verbal working memory performance is associated with negative 
symptoms but not positive symptoms. This study failed to detect association 
of smoking on verbal working memory. 
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Introduction 
 
Prevalence of smoking in patients with 
schizophrenia is up to four-fold higher 
compared the general population1. These 
observations remain true across cultures and 
countries and when controlling for possible 
confounders, such as marital and socio-
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 economic status, alcohol use, antipsychotic 
use, or institutionalism2. Patients with 
schizophrenia smoke more, favour stronger 
cigarettes and extract more nicotine from 
their cigarettes3. Several possible 
mechanisms have been hypothesized to 
explain the high prevalence of smoking seen 
in schizophrenia. Most of these suggest that 
nicotine serves as a form of self-medication 
to reduce the side effects of antipsychotic 
medications, to enhance the therapeutic 
effect of antipsychotics and so alleviate 
negative symptoms, and/or to ameliorate a 
number of cognitive deficits associated with 
schizophrenia4. 
 
Smoking high-nicotine cigarettes, compared 
to smoking de-nicotinized cigarettes was 
found to reduce negative symptoms without 
affecting positive symptoms5. This effect is 
thought to reflect nicotine’s ability to raise 
dopamine levels in the nucleus accumbens 
and prefrontal cortex6. Following from the 
view that negative symptoms results from 
hypodopaminergic tone in the frontal 
cortex7, it has been suggested that smoking 
provides a way of temporarily reducing 
these negative symptoms by raising 
dopamine levels in these regions8. In a phase 
2 trial of a nicotinic agonist in 
schizophrenia, DMXB-A which activates 
α7-nicotinic receptor was found to improve 
negative symptoms that are generally 
resistant to treatment with antipsychotics9. 
Cognitive impairment whilst less obvious 
than positive symptoms such as 
hallucinations and delusions, is now thought 
to be a core component of schizophrenia. 
Neuropsychological studies have 
consistently described deficits affecting 
attention, working memory, executive 
functioning, learning and memory in 
patients with schizophrenia10. 
 
Working memory provides a crucial 
interface between perception, attention, 
memory, and action, due to its involvement 
in complex cognitive functions such as 
learning, reasoning and comprehension11. It 
is limited in volume and time span, allowing 
the subject to operate with bits of recent 
information. Two subsystems namely the 
visuo-spatial sketchpad and the phonological 
loop have been described. The first one is 
represented by the working memory for 
visual and spatial information, and the 
second one is the short term memory for 
acoustic or speech based information. The 
two aforementioned subsystems are under 
the control of a central executive system11. 
Verbal memory is therefore regarded as a 
distinctive type of working memory, 
underlying encoding through language12. 
 
In a study by Cosman, patients with 
schizophrenia performed significantly 
poorer in all three working memory tests 
comprised of Word List Memory Test, Face 
Memory Test, and Spatial Working 
Memory13. On the other hand, studies have 
suggested that nicotine administration can 
improve attention and working memory 
deficits14,15. Overall, existing evidence 
points consistently towards the beneficial 
effect of smoking or nicotine on sustained 
attention and working memory functions in 
schizophrenia, perhaps to a greater extent 
than seen in healthy populations. Other 
cognitive functions may be less sensitive to 
the effects of nicotine or smoking.  
 
The assessment of working memory 
subsystems has been shown to provide 
invaluable information for the strategy of 
cognitive rehabilitation of schizophrenia 
patients, due to the fact that cognitive 
training exercises mainly involve working 
memory subsystems16. Therefore, this study 
aims to investigate the association of 
cigarette smoking with verbal memory (a 
part of working memory) and 
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 psychopathology of patients with 
schizophrenia. 
 
Methods 
 
Subject 
 
This is a cross sectional study on 30 smokers 
and 23 non-smokers with schizophrenia. 
Subjects were grouped into smoker if they 
smoke > 20 cigarettes per day and non-
smoker if they do not smoke or smoke less 
than 5 cigarettes for the previous 6 months. 
They were recruited from the outpatient 
clinic and psychiatric wards in Hospital 
Universiti Sains Malaysia (HUSM) within a 
six-month period (1st July 2011 till 31st 
December 2011). They were cooperative 
and able to understand the Malay language. 
Patients were excluded if they have mental 
retardation, neurological or significant 
medical problems; current or past histories 
of substance abuse other than nicotine, or 
were regularly prescribed with 
anticholinergic medication such as 
benzhexol. Anticholinergic drugs have been 
shown to have significant negative effects 
on the immediate memory and the verbal 
working memory17. 
 
The age limit of all subjects was set between 
15 and 65 years to minimize the effect of 
normal aging process on the cognitive 
performance. The study protocol was 
approved by the Research & Ethics 
Committee, Universiti Sains Malaysia and 
Ministry of Health. A single researcher (the 
first author) trained in psychiatric interview 
and rating scale interviewed all the subjects 
and administered the test individually. 
 
Assessment 
 
The Malay Version of Auditory Verbal 
Learning Test (MVAVLT) is a translated 
and validated Malay version of the Rey 
Auditory Verbal Learning Test, developed 
to suit the Malaysian population. It has good 
validity (factor analysis 0.66 to 0.98), test-
retest reliability (pearson correlation 0.24 to 
0.84) and sensitive in discriminating 
between normal and schizophrenia 
patients18. The MVAVLT consists of two 
different lists (A and B) of 15 concrete 
nouns each. Participants were asked to read 
the first list (A) five times (A1-A5) at a rate 
of one item per second (tape recording was 
used to standardize the rate). Free verbal 
recall (immediate memory) was tested 
immediately after each presentation. Total 
learning (A1 + A2 + A3 + A4 + A5) reflects 
the acquisition phase in the memory 
information processing operations. Then a 
second list (B) was presented followed by its 
free recall which acted as interference for 
A6. Thereafter, recall of list A (A6) was 
examined without prior presentation of list 
A. After 20 minutes of rest, recall of list A 
(A7) was repeated without its prior 
presentation. Finally, the participants had to 
recognize the words from list A interspersed 
among semantically or phonetically related 
words in a third list that comprised 30 
words. 
 
The Positive and Negative Syndrome Scale 
(PANSS) scale is a 30-item semi structured 
clinical interview specifically developed to 
assess for typological and dimensional 
assessment of schizophrenia. It has good 
psychometric properties with coefficients 
ranging from 0.73 to 0.83 for each of the 
scale19. There are 7 items for PANSS 
positive scale, 7 items for PANSS negative 
scale and 16 items for general 
psychopathology scale. Each items are rated 
on a 7-point scale (1= absent, 7 extreme). 
Rating is based upon information related to 
the past week. Total score for each group of 
symptoms were calculated by adding all the 
scores for the items in each group. 
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 Results 
 
Table 1 shows the socio-demographic and 
clinical variables of the study participants. 
The smoker and non-smoker groups did not 
differ significantly in age, age at first 
treatment, duration since first treatment and 
number of admission. The median age were 
35.5 and 38.6 years old, median age at first 
treatment 21.5 and 20 years old, median 
duration of treatment 12.5 and 17 years and 
median number of ward admission 5 and 6 
respectively. Both groups also did not differ 
significantly in ethnicity, marital status, 
employment status, educational level and 
type of antipsychotics. Majority of the 
participants was Malay (98.1%) and there 
was only one Chinese participant who is a 
smoker. Male comprised of 90% in smoker 
group compared to 39% in non-smoker 
group which is statistically a significant 
difference. Effect of gender on verbal 
learning from previous study has been 
inconclusive. A local study found that male 
patients performed better in verbal learning 
performance compared to female20.  
 
Table 1. Socio-Demographic and Clinical Characteristics of the Sample (n=53) 
  Smokers 
(n=30) 
Non-smokers 
(n=23) 
 
  Frequency 
(%) 
Frequency (%) Z* p-
value† 
Gender Male 27 (90) 9 (39)  <0.010 
 Female 3 (10) 14 (61)   
Ethnic Malay 29 (97) 23 (100)  0.566 
 Others 1 (3) 0 (0)   
Marital status Married 7 (23) 4 (17)  0.543 
 Single 15 (50) 15 (65)   
 Divorced 8 (26) 4 (17)   
Employment status Full time 1 (3) 2 (8)  0.460 
 Part time 12 (40) 6 (26)   
 Unemploye
d 
17 (57) 15 (66)   
Educational level Tertiary 0 (0) 1 (4)  0.051 
 Secondary 29 (97) 17 (74)   
 Primary 1 (3) 5 (22)   
Type of 
antipsychotics 
Atypical 
only 
14 (47) 10 (43)  0.460 
 Typical 
Only 
4 (13) 1 (4)   
 Combinatio
n 
12 (40) 12 (52)   
  Median (IQR) Median (IQR)   
Age (year) 35.5 (8.0) 38.7(8.0) -1.92 0.542 
Age at first treatment (year) 21.5 (11) 20 (10) -0.70 0.481 
Duration since first treatment (year) 12.5 (16) 17 (10) -1.21 0.230 
Number of ward admission 5 (8) 6 (9) -1.69 0.493 
*Mann-Whitney test. 
† Chi-Square test, P<0.05 as significant at 95% CI.
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 Table 2 shows that all of the participants had 
only minimal to mild psychiatric symptoms. 
For smokers the means (SD) scores in 
PANSS positive, negative and general 
psychopathology were 15.3 (5.12), 11.5 
(5.81) and 24.9 (7.17) while for non-
smokers the score were 14.0 (5.9), 
12.9(4.79) and 24.9 (5.25) respectively. 
Even though, smokers scored higher on 
PANSS positive and non-smokers scored 
higher on PANSS negative, these were not 
statically significant. Assessment with 
MVAVLT showed that there were 
significant differences in total A1-A5, A6, 
A7 and recognition between the 2 groups 
although the scores in smoker group were 
consistently higher than the non-smoker 
group in all 4 measures of immediate 
memory (total A1-A5), post-interference 
immediate memory (A6), delayed recall 
(A7) and recognition memory. 
 
Table 2. Psychopathology and Verbal Memory among Smokers and Non-Smokers with 
Schizophrenia 
 Smokers 
(n=30) 
Non-smokers 
(n=23) 
Statistical Analysis 
 Mean (SD) Mean (SD) Mean differences 
(95% CI) 
p-value 
PANSS     
 Positive 15.41 (5.12) 14.03(5.91) 1.37 (-1.691,4.421) 0.380 
 Negative 11.50 (5.81) 12.90(4.79) -1.42 (-4.350,1.501) 0.352 
 General 
Psychopathology 
24.93 (7.17) 24.90 (5.25) 0.01 (-3.562,3.583) 0.901 
MVAVLT     
 Total A1-A5 42.71(11.03) 37.52(11.53) 0.6 (-0.591,1.710) 0.260 
 A6 8.50(2.51) 7.84( (1.50) 0.2 (-0.680,1.052) 0.671 
 A7 9.41(2.53) 8.43(2.562) 0.9 (-0.490,2.351) 0.190 
 Recognition 14.00(2.02) 13.10(1.421) 0.6 (-0.191,1.400) 0.140 
 
 
Simple linear regression analysis was done 
to determine the potential associated factors 
for verbal working memory among the 
subjects. Total A1-A5 scores of MVAVLT 
were chosen as dependent factor for the 
analysis since the scores measure immediate 
memory which reflects the verbal working 
memory of the subjects. Eight variables with 
p-value of less than 0.25, which include 
employment status, educational level, 
smoking status, number of admission, type 
of antipsychotics and all PANSS subscales, 
were further analysed using multiple linear 
regression. In the final model, the result 
shows that the higher the number of 
admission to ward and also, the more severe 
the negative symptoms or general 
psychopathology of schizophrenia, the lower 
the memory performance. There was also 
association between type of antipsychotics 
and memory, atypical showing better 
memory performance compared to typical 
antipsychotics or combination. 
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 Table 3. Simple and Multiple Linear Regression Analysis to Determine Factors Associated with 
Verbal Working Memory in Patients with Schizophrenia 
 SLR* MLR‡ 
 B†  (95% CI) t Stat p-
value 
B§ (95% CI) t Stat p-
value 
Age 0.151 (-
0.285,0.596) 
0.69 0.491    
Gender -0.574 
(17.397,6.25) 
-0.167 0.870    
Ethnicity 3.635 (-19.759, 
27.028) 
0.312 0.762    
Marital status 1.330 (-3.494, 
6.154) 
0.554 0.582    
Employment status -5.153 (-10.254, 
-0.052) 
-2.028 0.048 -0.054 (-5.526, 
3.503) 
-
0.452 
0.654 
Educational level -7.072 (-45.929, 
1.785) 
-1.603 0.115 -4.198 (-11.610, 
3.215) 
-
1.139 
0.260 
Smoking status -5.145 (-11.408, 
1.118) 
-1.65 0.108 -0.149 (-8.443, 
1.616) 
-
1.368 
0.178 
Age at first treatment 
(year) 
0.075 (-0.435, 
0.585) 
0.295 0.773    
Duration since first 
treatment (year) 
0.022 (-0.335, 
0.379) 
0.123 0.902    
Number of ward 
admission 
-0.810 (-1.427, -
0.193) 
-2.63 0.011 -0.623 (-1.120, -
0.126) 
-2.52 0.015 
Type of 
antipsychotics 
2.771 (-0.485, 
6.027) 
1.709 0.094 3.080 
(0.598,5.562) 
2.49 0.016 
PANNS positive -0.533 (-1.100, 
0.035) 
-1.885 0.065 -0.052 (-0.552, 
0.449) 
-
0.207 
0.837 
PANSS negative -1.170 (-1.669, -
0.672) 
-4.711 0.000 -1.011(-1.460,-
0.562) 
-4.59 0.000 
PANSS general -0.590 (-1.069, -
0.111) 
-2.475 0.017 -0.450 (-0.796, -
0.034) 
-2.19 0.034 
*Simple Linear Regression (outcome as mean stigma score) 
† Crude regression coefficient. 
‡ There is no significant interaction; no multi colinearity problem; and linearity, normality and 
equal variance assumptions were made. 
§ Adjusted regression coefficient. 
 
Discussion 
 
This study found better verbal working 
memory performance is associated with 
lower number of admission, use of atypical 
antipsychotics, lower negative symptoms 
and general psychopathology among 
patients with schizophrenia. No significant 
association was found between verbal 
working memory performance and smoking 
status. 
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 The association between verbal working 
memory performance and lower negative 
symptoms is consistent with a previous 
study by Cameron21 which measure 
psychopathology using PANSS in a sample 
of 58 patients with schizophrenia. It was 
concluded that working memory deficit was 
associated with severity of negative 
symptoms but not with positive symptoms. 
Working memory deficit was also associated 
with severity of disorganised dimension 
comprised of conceptual disorganization 
(P2), difficulty in abstract thinking (N5), 
disorientation (G10), and poor attention 
(G11) which also explained the positive 
association with general psychopathology 
subscale in this study. A more recent study 
by McDowd et al indicated that verbal 
memory, processing speed and negative 
symptoms were inter-related and 
significantly contributed to functional status 
directly and mediated by the other factors22.  
 
The association between verbal working 
memory performance and use of atypical 
antipsychotics is consistent with many 
previous studies. For example a study by 
Mori et al23 suggested that switching chronic 
schizophrenic patients to risperidone or 
olanzapine improved the immediate 
memory. Risperidone and olanzapine have 
been suggested to promote the release of 
acetylcholine in the medial prefrontal 
cortex24. Improvement of the immediate 
memory by olanzapine and risperidone 
increased further when anticholinergic drugs 
were withdrawn. On the other hand, the 
immediate memory became worse after 
switching to quetiapine suggesting a strong 
connection between the immediate memory 
and the anticholinergic effect of drug 
therapy.  
 
This study did not find significant 
association between verbal memory 
performance and smoking status which is 
consistent with study by Harris et al25 which 
failed to detect positive effects of nicotine 
on tests of immediate or delayed memory, 
language or visuo-spatial attention. Nicotine 
nasal spray was reported to improve spatial 
accuracy and verbal memory5. Nicotine 
administered via patches to smoking 
deprived schizophrenia patients was 
reported to improve their performance on a 
task involving working memory and 
attention26. 
 
The main limitations of this study are its 
cross sectional design and small sample size. 
A better design will compare cognitive 
performance during nicotine abstinence and 
administration in subjects with 
schizophrenia. The use of nicotine spray or 
patch is preferable compared to patient’s 
verbal report on the amount of cigarettes 
smoke which may not be accurate. Another 
poorly controlled confounder in this study is 
the use of antipsychotics. Antipsychotics use 
is different not only with regard to atypical, 
typical and combined, but also in their 
intrinsic anticholinergic activity23. Future 
study should consider all the subjects using 
only one or a few but very similar 
antipsychotics. 
 
References 
 
1. de Leon J, Diaz FJ. A meta-analysis 
of worldwide studies demonstrates 
an association between schizophrenia 
and tobacco smoking behaviors. 
Schizophr Res. 2005; 76:135–157 
 
2. de Leon J, Becona E, Gurpegui M, 
Gonzalez-Pinto A, Diaz FJ. The 
association between high nicotine 
dependence and severe mental illness 
may be consistent across countries. J 
Clin Psychiatry 2002; 63:812–816 
 
50
Malaysian Journal Of Psychiatry, June 2012, Vol. 21, No. 1
 3. Olincy A, Johnson LL, Ross RG. 
Differential effects of cigarette 
smoking on performance of a smooth 
pursuit and a saccadic eye movement 
task in schizophrenia. Psychiatry 
Res. 2003; 117:223–236 
  
4. Kumari V, Postma P. Nicotine use in 
schizophrenia: The self-medication 
hypotheses. Neuroscience & 
Biobehavioral Reviews, 2005; 
29(6):1021-1034 
 
5. Smith RC, Singh A, Infante M, 
Khandat A, Kloos A (2002) Effects 
of cigarette smoking and nicotine 
nasal spray on psychiatric symptoms 
and cognition in schizophrenia. 
Neuropsychopharmacology 2002; 
27:479–497 
 
6. Corrigall WA, Coen KM. Selective 
dopamine antagonists reduce 
nicotine self-administration. 
Psychopharmacology (Berl), 1991; 
104(2), 171-6 
 
7. Weinberger DR, Berman KF. 
Speculation on the meaning of 
cerebral metabolic hypofrontality in 
schizophrenia. Schizophr. Bull. 
1988; 14(2): 157–168 
 
8. Dalack GW, Healy DJ, Meador-
Woodruff JH. Nicotine dependence 
in schizophrenia: clinical phenomena 
and laboratory findings. Am J 
Psychiatry. 1998; 155(11), 1490-501 
 
9. Freedman R, Olincy A, Buchanan 
RW; Harris JG, Gold JM, Johnson L, 
et al. Initial phase 2 trial of a 
nicotiniv antagonist in schizophrenia. 
Am J Psychiatry. 2008; 165(8):1040-
1047 
 
10. Heinrichs RW, Zakzanis KK. 
Neurocognitive deficit in 
schizophrenia: a quantitative review 
of the evidence. Neuropsychology. 
1998; 12:426–445  
 
11. Baddeley AD. The fractionation of 
working memory. Proceedings of the 
National Academy of Sciences of the 
United States of America. 1996; 93: 
13468–13472 
 
12. Barch DM, Csernansky JG. 
Abnormal parietal cortex activation 
during working memory in 
schizophrenia verbal phonological 
coding disturbances versus domain-
general executive dysfunction. Am J 
Psychiatry. 2007; 164: 1090-1098 
 
13. Cosman D, Nemes B, Nica S, Herła 
DC. Verbal, visuo-spatial and face 
working memory impairment in 
multiple episode schizophrenia 
patients. Journal of Cognitive and 
Behavioral Psychotherapies. 2009; 
9(1), 21-32 
 
14. Zabala A, Eguiluz JI, Segarra R, 
Enjuto S, Ezcurra J, Gonzalez PA, 
Gutierrez M. (2009). Cognitive 
performance and cigarette smoking 
in first-episode psychosis. Eur Arch 
Psychiatry Clin Neurosci. 2009; 
259(2), 65-71 
 
15. Barr RS, Culhane MA, Jubelt LE, 
Mufti RS, Michael A Dyer MA, 
Weiss AP, Deckersbach T, Kelly JF, 
Oliver Freudenreich O, Goff DC, and 
Evins AE. The Effects of 
Transdermal Nicotine on Cognition 
in Nonsmokers with Schizophrenia 
and Nonpsychiatric Controls 
Neuropsychopharmacology. 2008; 
33: 480–490 
51
Malaysian Journal Of Psychiatry, June 2012, Vol. 21, No. 1
 16. Wykes T, Brammer M, Mellers J, 
Bray P, Reeder C, Williams C, 
Corner J. Effects on the brain of a 
psychological treatment: cognitive 
remediation therapy. Functional 
magnetic resonance imaging in 
schizophrenia. Br J Psychiatry. 2002; 
181, 144-152 
 
17. Mori K, Yamashita H, Nagao M, 
Horiguchi J, Yamawaki S. Effects of 
anticholinergic drug withdrawal on 
memory, regional cerebral blood 
flow and extrapyramidal side effects 
in schizophrenic patients. 
Pharmacopsychiatry. 2002; 35, 6–11 
 
18. Ruzita J, Zahiruddin O, Kamarul IM, 
Muhammad Najib MA. Validation of 
the Malay Version of Auditory 
Verbal Learning Test (MVAVLT) 
among schizophrenia patients in 
Hospital Universiti Sains Malaysia 
(HUSM), Malaysia, ASEAN J 
Psychiatry. 2009; 10(1) 
 
19. Kay SR, Fiszbein A, Opler LA. The 
positive and negative syndrome scale 
(PANSS) for schizophrenia. 
Schizophr Bull. 1987; 13(2):261-76 
 
20. Zahiruddin O, Ruzita J, Muhammad 
Najib M A, Hasanah CI. 
Demographic and clinical factors 
associated with verbal memory 
performance in patients with 
schizophrenia in Hospital Universiti 
Sains Malaysia (HUSM), Malaysia. 
ASEAN J Psychiatry, 2011; 12(2) 
 
21. Cameron AM, Oram J, Geffen GM, 
Kavanagh DJ, McGrath JJ, Geffen 
LB. Working memory correlates of 
three symptom clusters in 
schizophrenia. Psychiatry Res. 2002; 
110(1), 49-61 
 
22. McDowd J, Tang TC, Tsai PC, 
Wang SY, Su CY. The association 
between verbal memory, processing 
speed, negative symptoms and 
functional capacity in schizophrenia. 
Psychiatry Res 2011;187: 329–334 
 
23. Mori K, Nagaoa M, Yamashita H, 
Morinobu S, Yamawaki S. Effect of 
switching to atypical antipsychotics 
on memory in patients with chronic 
schizophrenia. Progress in Neuro-
Psychopharmacology & Biological 
Psychiatry. 2008;28: 659– 665 
 
24. Ichikawa J, Dai J, O’Laughlin IA, 
Fowler WL, Meltzer HY. Atypical, 
but not typical, antipsychotic drugs 
increase cortical acetylcholine 
release without an effect in the 
nucleus accumbens or striatum. 
Neuropsychopharmacology. 2002; 
26: 325–339 
 
25. Harris JG, Kongs S, Allensworth D, 
Martin L, Tregellas J, Sullivan B, 
Zerbe G, Freedman R. Effects of 
nicotine on cognitive deficits in 
schizophrenia. 
Neuropsychopharmacology 2004; 29 
(7): 1378–1385 
 
26. Jacobsen LK, D’Souza DC, Mencl 
WE, Pugh KR, Skudlarski P, Krystal 
JH. Nicotine effects on brain 
function and functional connectivity 
in schizophrenia. Biol. Psychiatry. 
2004; 55 (8): 850–858 
 
 
 
52
Malaysian Journal Of Psychiatry, June 2012, Vol. 21, No. 1
 Corresponding Author 
Dr. Zahiruddin Othman 
Department of Psychiatry, 
School of Medical Sciences, 
Universiti Sains Malaysia, 
16150 Kubang Kerian, Malaysia 
 
Email: zahir@kb.usm.my 
53
Malaysian Journal Of Psychiatry, June 2012, Vol. 21, No. 1
